The intention-to-treat pCR rate was 23.4 % ( 95 % confidence interval [ CI ] 11.2-35 .6 % ) in arm A and 38 % ( 95 % CI 24.5 % to 51.5 % ) in arm B. With a median follow-up duration of 30.3 months , the 2-year progression-free survival rate was 58.4 % in arm A and 58.6 % in arm B , whereas the 2-year overall survival rate was 60.7 % and 63.7 % , respectively .